$15.25−0.16 (−1.04%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Neogenomics (NEO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~10.7%/yr (FY21→FY25), net margin −14.9%. Worth your attention in FY25: Share count (+6.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲10.1%
727.3
FY21→FY25CAGR +10.7%/yr
Net income ($M)▼37.2%
−108.0
one-off year: see footnoteCAGR —
Free cash flow ($M)▲36.0%
−21.8
FY21→FY25CAGR —
Diluted EPS▼35.5%
−0.84
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+6.8%
120.0mn → 128.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$27.0M
−34.2% YoY in FY25 · 3.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-15¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 38.6% → 43.2%. Net margin -14.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 787.8 | 727.3 | 660.6 | 591.6 | 509.7 | 484.3 | ▲10.1% | +10.7% |
Cost of revenue | 435.1 | 413.0 | 370.5 | 347.0 | 321.8 | 297.3 | ▲11.5% | +8.6% |
Gross profit | 352.7 | 314.3 | 290.1 | 244.6 | 187.9 | 187.1 | ▲8.3% | +13.9% |
Research & development | 39.3 | 37.1 | 31.2 | 27.3 | 30.3 | 21.9 | ▲19.0% | +14.1% |
Selling, general & admin | 259.9 | 273.3 | 259.7 | 243.1 | 243.4 | 221.3 | ▲5.2% | +5.4% |
Total operating expenses | 402.0 | 430.2 | 382.2 | 352.3 | 345.5 | 305.8 | ▲12.6% | +8.9% |
Operating incomefeeds ROC rank | −49.4 | −115.9 | −92.1 | −107.7 | −157.6 | −118.8 | ▼25.8% | — |
Other income, net | 13.2 | 5.6 | 11.4 | 10.6 | −1.7 | 103.7 | — | — |
Pretax income | −36.2 | −110.3 | −80.7 | −97.1 | −159.3 | −15.1 | ▼36.7% | — |
Income tax | −3.9 | −2.2 | −1.9 | −9.1 | −15.1 | −6.7 | ▼15.1% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −32.3 | −108.0 | −78.7 | −88.0 | −144.3 | −8.3 | ▼37.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.25 | −0.84 | −0.62 | −0.70 | −1.16 | — | ▼35.5% | — |
Diluted shares (mn) | 128.59 | 128.10 | 126.66 | 125.50 | 124.22 | 119.96 | ▲1.1% | +1.7% |
| Margins | ||||||||
Gross margin24th pct in Healthcare | 44.8% | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | ▼0.7pp | +4.6pp |
Operating margin | −6.3% | −15.9% | −13.9% | −18.2% | −30.9% | −24.5% | ▼2.0pp | +8.6pp |
Net margin33rd pct in Healthcare | −4.1% | −14.9% | −11.9% | −14.9% | −28.3% | −1.7% | ▼2.9pp | −13.1pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 45% vs a 9% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 11 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Neogenomics' revenue last fiscal year?
Neogenomics reported revenue of $727.3M in fiscal 2025, up 10.1% from fiscal 2024.
What was Neogenomics' net income?
Neogenomics reported net income of −$108.0M in fiscal 2025, a net margin of −14.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

